Loading...
•
Dec 31, 2022
Day One Q4 2022 Earnings Report
Announced fourth quarter and full year 2022 financial results and highlighted recent corporate achievements.
Key Takeaways
Day One Biopharmaceuticals reported its Q4 and full year 2022 financial results, highlighting the first patient dosed in the pivotal Phase 3 FIREFLY-2/LOGGIC trial and positive topline data from the Phase 2 FIREFLY-1 trial.
First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG).
Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meaningful responses with tovorafenib (DAY101) in relapsed or progressive pLGG.
Additional data from FIREFLY-1 planned for presentation at a medical meeting in second quarter of 2023.
New Drug Application (NDA) submission planned for tovorafenib (DAY101) in first half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...